These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35835468)

  • 1. SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.
    Meyer-Arndt L; Braun J; Fauchere F; Vanshylla K; Loyal L; Henze L; Kruse B; Dingeldey M; Jürchott K; Mangold M; Maraj A; Braginets A; Böttcher C; Nitsche A; de la Rosa K; Ratswohl C; Sawitzki B; Holenya P; Reimer U; Sander LE; Klein F; Paul F; Bellmann-Strobl J; Thiel A; Giesecke-Thiel C
    J Neurol Neurosurg Psychiatry; 2022 Sep; 93(9):960-971. PubMed ID: 35835468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
    Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
    Front Immunol; 2022; 13():868915. PubMed ID: 35432335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
    Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L
    J Neurol; 2023 May; 270(5):2380-2391. PubMed ID: 36933032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects.
    Maniscalco GT; Ferrara AL; Liotti A; Manzo V; Di Battista ME; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Alfieri G; Di Iorio W; Della Rocca G; Andreone V; De Rosa V
    Mult Scler Relat Disord; 2022 Jun; 62():103800. PubMed ID: 35462168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
    Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
    Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients: Correlations with DMTs and clinical variables.
    Barone S; Palmieri C; Gallelli L; Rania V; Pascarella A; Abatino A; Bruno PA; Casarella A; Pasquale M; Manzo L; De Sarro G; Gambardella A; Valentino P
    Neurotherapeutics; 2024 Mar; 21(2):e00307. PubMed ID: 38237381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis.
    Kanakura M; Kihara K; Kinoshita M; Sugimoto T; Murata H; Beppu S; Shiraishi N; Sugiyama Y; Koda T; Takahashi MP; Chinen I; Okuno T; Mochizuki H
    Clin Neurol Neurosurg; 2024 Aug; 243():108378. PubMed ID: 38901377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
    Rabenstein M; Thomas OG; Carlin G; Khademi M; Högelin KA; Malmeström C; Axelsson M; Brandt AF; Gafvelin G; Grönlund H; Kockum I; Piehl F; Lycke J; Olsson T; Hessa T
    Eur J Neurol; 2023 Dec; 30(12):3789-3798. PubMed ID: 37522464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
    Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
    Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination.
    Orrù V; Serra V; Marongiu M; Lai S; Lodde V; Zoledziewska M; Steri M; Loizedda A; Lobina M; Piras MG; Virdis F; Delogu G; Marini MG; Mingoia M; Floris M; Masala M; Castelli MP; Mostallino R; Frau J; Lorefice L; Farina G; Fronza M; Carmagnini D; Carta E; Pilotto S; Chessa P; Devoto M; Castiglia P; Solla P; Zarbo RI; Idda ML; Pitzalis M; Cocco E; Fiorillo E; Cucca F
    Front Immunol; 2024; 15():1416464. PubMed ID: 39076966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
    Tortorella C; Aiello A; Gasperini C; Agrati C; Castilletti C; Ruggieri S; Meschi S; Matusali G; Colavita F; Farroni C; Cuzzi G; Cimini E; Tartaglia E; Vanini V; Prosperini L; Haggiag S; Galgani S; Quartuccio ME; Salmi A; Repele F; Altera AMG; Cristofanelli F; D'Abramo A; Bevilacqua N; Corpolongo A; Puro V; Vaia F; Capobianchi MR; Ippolito G; Nicastri E; Goletti D;
    Neurology; 2022 Feb; 98(5):e541-e554. PubMed ID: 34810244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
    Apostolidis SA; Kakara M; Painter MM; Goel RR; Mathew D; Lenzi K; Rezk A; Patterson KR; Espinoza DA; Kadri JC; Markowitz DM; E Markowitz C; Mexhitaj I; Jacobs D; Babb A; Betts MR; Prak ETL; Weiskopf D; Grifoni A; Lundgreen KA; Gouma S; Sette A; Bates P; Hensley SE; Greenplate AR; Wherry EJ; Li R; Bar-Or A
    Nat Med; 2021 Nov; 27(11):1990-2001. PubMed ID: 34522051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
    Tütüncü M; Demir S; Arslan G; Dinç Ö; Şen S; Gündüz T; Uzunköprü C; Gümüş H; Tütüncü M; Akçin R; Özakbaş S; Köseoğlu M; Bünül SD; Gezen O; Tezer DÇ; Baba C; Özen PA; Koç R; Elverdi T; Uygunoğlu U; Kürtüncü M; Beckmann Y; Doğan İG; Turan ÖF; Boz C; Terzi M; Tuncer A; Saip S; Karabudak R; Kocazeybek B; Efendi H; Bilge U; Siva A
    Mult Scler Relat Disord; 2023 Jul; 75():104761. PubMed ID: 37247488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three to four mRNA COVID-19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization.
    Louapre C; Belin L; Marot S; Hippolyte A; Januel E; Ibrahim M; Jeantin L; Zafilaza K; Malet I; Charbonnier-Beaupel F; Rosenzwajg M; Soulié C; Marcelin AG; Pourcher V
    Eur J Neurol; 2023 Sep; 30(9):2781-2792. PubMed ID: 37310391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
    Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
    Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
    Front Immunol; 2021; 12():781843. PubMed ID: 34956211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies.
    Capone F; Lucchini M; Ferraro E; Bianco A; Rossi M; Cicia A; Cortese A; Cruciani A; De Arcangelis V; De Giglio L; Motolese F; Sancetta B; Mirabella M; Di Lazzaro V
    Neurotherapeutics; 2022 Jan; 19(1):325-333. PubMed ID: 34859382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.
    Achiron A; Mandel M; Dreyer-Alster S; Magalashvili D; Menascu S; Warszawer Y; Dolev M; Didikin M; Harari G; Sonis P; Falb R; Gurevich M
    Mult Scler Relat Disord; 2023 Apr; 72():104616. PubMed ID: 36933299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
    Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
    EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.